We are excited to share the latest prospective findings from a study entitled “Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer”.1

This study, led by Evelyn Klein and her team, sheds light on the invaluable role of the EndoPredict test in guiding chemotherapy decisions for patients with early-stage hormone receptor-positive, HER2-negative breast cancer.

This real-world study enrolled 368 patients with 0-3 positive lymph nodes at the interdisciplinary breast center of Klinikum rechts der Isar, Technical University Munich (TUM). The EndoPredict test classified  65% of patients into low-risk and 35% into high-risk for distant recurrence. The reported median follow-up time was 8.2 years.

Key Study Findings

  • Distant metastasis-free survival: The EPclin low-risk group demonstrated a 5-year metastasis-free survival rate of 96.6%, compared to 85.5% in the EPclin high-risk group. EPclin high-risk patients were at a significant higher risk of experiencing distant relapse or cancer-related death.
  • Chemotherapy benefit: EPclin high-risk patients who received chemotherapy experienced a substantial improvement in 5-year disease-free survival (DFS) compared to those who did not, highlighting the efficacy of EndoPredict to identify patients who can benefit from chemotherapy.
  • Menopausal status: EndoPredict risk stratification also appears to be applicable in premenopausal women.
  • Ki67 comparison: The study revealed that EndoPredict provides a more precise estimation of prognosis compared to Ki-67 subtypes.

“In our study we found compelling prospective evidence supporting the use of the EndoPredict test in guiding adjuvant chemotherapy decisions for early ER-positive, HER2-negative breast cancer” states PD Dr. Evelyn Klein. “Furthermore, the EndoPredict test showed a better classification accuracy in comparison to Ki67 subtypes, resulting in a more precise estimation of prognosis and we demonstrated prospectively the chemotherapy benefit prediction provided by the EndoPredict test.”

We believe that these findings underscore the role of EndoPredict in guiding personalized breast cancer treatment decisions, optimizing outcomes for patients by accurately assessing the risk of recurrence and individual chemotherapy benefit.

We encourage you to delve into the full study for deeper insights.

What is EndoPredict®?

EndoPredict® is a prognostic and predictive test combining molecular and clinical factors that provides individualized results, allowing you to make confident decisions about adjuvant chemotherapy and the possibility to stop endocrine therapy after 5 years in ER+/HER2-early-stage breast cancer.

EndoPredict gives clear results and actionable insights for treatment decisions:

  • Distant recurrence risk within years 0–102
  • Absolute individualized chemotherapy benefit at 10 years3
  • Late distant recurrence risk up to 15 years4

Gain timely access to genomic insights fostering a pathway to better patient outcomes.

EndoPredict® is provided by Myriad Genetics, committed to improving timely access to genomic insights, through local testing, education and partnerships.


  1. Klein E. et al. Breast Cancer Res. Treat. 2024
  2. Filipits M. et al. Clin. Cancer Res. 2011
  3. Sestak I. et al. Breast Cancer Res Treat. 2019
  4. Filipits M. et al. Clin Cancer Res. 2019